Chemotherapy- and hormone-induced histologic changes in tumours

Current Diagnostic Pathology

Volumn 9, Issue 2, 2003, Pages 137-147

  Chan, J K C ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Chemotherapy; Cytodifferentiation; Hormonal therapy; Tumour maturation; Tumour necrosis

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; FINASTERIDE; FLUTAMIDE; GONADORELIN; LEUPRORELIN; STEROID;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; CELL DAMAGE; CELL DIFFERENTIATION; CONFERENCE PAPER; HISTOLOGY; HORMONAL THERAPY; HUMAN; STEROID THERAPY; TUMOR;

EID: 0037390064     PISSN: 09686053     EISSN: None     Source Type: Journal    
DOI: 10.1054/cdip.2003.0161     Document Type: Conference Paper

References (57)

1. Lowichik A, Zhou H, Pysher T J et al. Therapy associated changes in childhood tumors. Adv Anat Pathol 2000; 7: 341-359.
2. Gil-Diez de Medina S, Salomon L, Colombel M et al. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol 1998; 29: 1005-1012.
3. Balk S P. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002; 60: 132-138, discussion 138-139.
4. Feldman B J, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
5. Oosterhuis J W, de Jong B, Cornelisse C J et al. Karyotyping and DNA flow cytometry of mature residual teratoma after intensive chemotherapy of disseminated nonseminomatous germ cell tumor of the testis: a report of two cases. Cancer Genet Cytogenet 1986; 22: 149-157.
6. Ulbright T M, Amin M B, Young R H. Tumors of the Testis, Adnexa, Spermatic Cord, and Scrotum. Atlas of Tumor Pathology, Series 3, Fascicle 25. Washington DC: Armed Forces Institute of Pathology, 1999.
7. Dyke P C, Mulkey D A. Maturation of ganglioneuroblastoma to ganglioneuroma. Cancer 1967; 20: 1343-1349.
8. Evans A E, Gerson J, Schnaufer L. Spontaneous regression of neuroblastoma. Natl Cancer Inst Monogr 1976; 44: 49-54.
9. Haas D, Ablin A R, Miller C, Zoger S, Matthay K K. Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer 1988; 62: 818-825.
10. Coffin C M, Rulon J, Smith L, Bruggers C, White F V. Pathologic features of rhabdomyosarcoma before and after treatment: a clinicopathologic and immunohistochemical analysis. Mod Pathol 1997; 10: 1175-1187.
11. Smith L M, Anderson J R, Coffin C M. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS). Med Pediatr Oncol 2002; 38: 398-404.
12. Shia J, Tickoo S K, Guillem J G et al. Increased endocrine cells in treated rectal adenocarcinomas: a possible reflection of endocrine differentiation in tumor cells induced by chemotherapy and radiotherapy. Am J Surg Pathol 2002; 26: 863-872.
13. Malawer M M, Link M P, Donaldson S S. Sarcomas of bone. In: DeVita VTJ, Hellma S, Rosenberg SA (eds). Cancer, Principles and Practice of Oncology, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2000; 1891-1935.
14. Raymond A K, Chawla S P, Carrasco C H et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol 1987; 4: 212-236.
15. Rosen G, Caparros B, Huvos A G et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-1230.
16. Huvos A G, Rosen G, Marcove R C. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977; 101: 14-18.
17. Picci P, Bacci G, Campanacci M et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 1985; 56: 1515-'1521.
18. Wold L E. Practical approach to processing osteosarcomas in the surgical pathology laboratory. Pediatr Dev Pathol 1998; 1: 449-454.
19. Raymond A K, Ayala A G. Specimen management after osteosarcoma chemotherapy. In: Unni KK (ed.). Bone Tumors. Contemporary Issues in Surgical Pathology, Vol. II. New York: Churchill Livingstone, 1988; 157-181.
20. Sharkey F E, Addington S L, Fowler L J, Page C P, Cruz A B. Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod Pathol 1996; 9: 893-900.
21. Sataloff D M, Mason B A, Prestipino A J et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995; 180: 297-306.
22. Aktepe F, Kapucuoglu N, Pak I. The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. Histopathology 1996; 29: 63-67.
23. Moll U M, Chumas J. Morphologic effects of neoadjuvant chemotherapy in locally advanced breast cancer. Pathol Res Pract 1997; 193: 187-196.
24. Tomczykowski J, Szubstarski F, Kurylcio L et al. Does the degree of cell lesion in breast cancer after inductive chemotherapy have any prognostic value? Acta Oncol 1999; 38: 949-953.
25. Rasbridge S A, Gillett C E, Seymour A M et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 1994; 70: 335-341.
26. Kennedy S, Merino M J, Swain S M, Lippman M E. The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue. Hum Pathol 1990; 21: 192-198.
27. Fisher E R, Wang J, Bryant J et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002; 95: 681-695.
28. Bullock M J, Srigley J R, Klotz L H, Goldenberg S L. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial. Am J Surg Pathol 2002; 26: 1400-1413.
29. Armas O A, Aprikian A G, Melamed J et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994; 18: 979-991.
30. Civantos F, Soloway M S, Pinto J E. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol 1996; 14: 22-31.
31. Civantos F, Marcial M A, Banks E R et al. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer 1995; 75: 1634-1641.
32. Drew P A, Murphy W M, Kubilis P S, Areford M. Can androgen deprivation with leuprolide be predicted from histology alone? If not, why not? J Urol 1997; 157: 2201-2205.
33. Murphy W M, Soloway M S, Barrows G H. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 1991; 68: 821-828.
34. Tran T A, Jennings T A, Ross J S, Nazeer T. Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy. Am J Surg Pathol 1998; 22: 347-354.
35. Mizoe A, Yamaguchi J, Azuma T et al. Transcatheter arterial embolization for advanced hepatocellular carcinoma resulting in a curative resection: report of two cases. Hepatogastroenterology 2000; 47: 1706-1710.
36. Yoshida T, Kanai T, Monden M et al. [Immunological and histological analyses of transarterial immuno-embolization therapy (TIE) in operable patients with hepatocellular carcinoma]. Gan To Kagaku Ryoho 1994; 21: 2111-2114.
37. Adachi E, Matsumata T, Nishizaki T et al. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer 1993; 72: 3593-3598.
38. Dai Y. [Histopathologic study on resected hepatocellular carcinoma after transcatheter hepatic arterial chemo-embolization]. Zhonghua Yi Xue Za Zhi 1991; 71: 366-368.
39. Di Carlo V, Ferrari G, Castoldi R et al. Pre-operative chemoembolization of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology 1998; 45: 1950-1954.
40. Guo W J, Yu E X. Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma. Br J Radiol 2000; 73: 1091-1097.
41. Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases. Cancer 1994; 73: 2259-2267.
42. Huang J, He X, Lin X, Zhang C, Li J. Effect of preoperative transcatheter arterial chemoembolization on tumor cell activity in hepatocellular carcinoma. Chin Med J (Engl) 2000; 113: 446-448.
43. Majno P E, Adam R, Bismuth H et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 226:688-701; discussion 1997; 701-703.
44. Nagashima J, Okuda K, Tanaka M, Sata M, Aoyagi S. Prognostic benefit in cytoreductive surgery for curatively unresectable hepatocellular carcinoma - comparison to transcatheter arterial chemoembolization. Int J Oncol 1999; 15: 1117-1123.
45. Rose D M, Chapman W C, Brockenbrough A T et al. Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma. Am J Surg 1999; 177: 405-410.
46. Stefanini G F, Amorati P, Biselli M et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 1995; 75: 2427-2434.
47. Zhang Z, Liu Q, He J et al. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer 2000; 89: 2606-2612.
48. Einhorn L H, Williams S D, Mandelbaum I, Donohue J P. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 1981; 48: 904-908.
49. Ulbright T M, Roth L M. Evaluation of germ cell tumors following chemotherapy. In: Talerman A, Roth L M (eds). Pathology of the Testis and its Adnexa. Contemporary Issues in Surgical Pathology, Vol. 7. New York: Churchill Livingstone, 1986; 231-241.
50. Ulbright T M, Roth L M. A pathologic analysis of lesions following modern chemotherapy for metastatic germ-cell tumors. Pathol Annu 25 Pt 1990; 1: 313-340.
51. Davey D D, Ulbright T M, Loehrer P J et al. The significance of atypia within teratomatous metastases after chemotherapy for malignant germ cell tumors. Cancer 1987; 59: 533-539.
52. Ulbright T M, Loehrer P J, Roth L M et al. The development of nongerm cell malignancies within germ cell tumors. A clinicopathologic study of 11 cases. Cancer 1984; 54: 1824-1833.
53. Geppert M, Ostertag C B, Seitz G, Kiessling M. Glucocorticoid therapy obscures the diagnosis of cerebral lymphoma. Acta Neuropathol (Berl) 1990; 80: 629-634.
54. Schwechheimer K, Braus D F, Schwarzkopf G et al. Polymorphous high-grade B cell lymphoma is the predominant type of spontaneous primary cerebral malignant lymphomas. Histological and immunomorphological evaluation of computed tomographyguided stereotactic brain biopsies. Am J Surg Pathol 1994; 18: 931-937.
55. Evoli A, Batocchi A P, Palmisani M T, Lo Monaco M, Tonali P. Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 1992; 32: 37-43.
56. Muller-Hermelink H K, Marx A, Kirchner T. Advances in the diagnosis and classification of thymic epithelial tumours. In: Anthony PP, MacSween RNM (eds). Recent Advances in Histopathology, Edinburgh, Churchill Livingstone, 1994; 49-72.
57. Chan J K C. Tumors of the lymphoreticular system, including spleen and thymus. In: Fletcher CDM (ed.). Diagnostic Histopathology of Tumors, 2nd edn. London: Churchill Livingstone, 2000; 1099-1316.